Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Palo Alto Institute for Research and Education, Inc.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Allergan
Information provided by:
Palo Alto Institute for Research and Education, Inc
ClinicalTrials.gov Identifier:
NCT00282958
First received: January 25, 2006
Last updated: NA
Last verified: January 2006
History: No changes posted

January 25, 2006
January 25, 2006
February 2003
Not Provided
NDI, VAS, SF-36
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain
The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain

To determine the therapeutic efficacy of Botox not only for chronic cervical/upper back pain but also for subacute pain.

Subjects diagnosed with subacute (2-6 months post-onset) bilateral cervical/ upper back pain will be recruited in this double-blind control study.

A total of 30 subjects with subacute cervical/upper back pain will be recruited. If patients are qualified as participants and agreed to participate in the study by signing the consent form, they will be randomized into either (A) control group (injection of normal saline injection) or (B) study group (injection of BOTOX). The initial history taking step will include medical history including medication and surgery history, duration of pain, pre-injection neck disability index (NDI) and visual analogue scale (VAS) for pain. VAS score will be collected for 4 weeks before injection to ensure stable VAS, otherwise medical records will be reviewed to ensure stable feature of pain. Short Form (SF) –36 Health Survey will be used to assess functional status, and the Beck Depression Inventory (BDI) will be applied to assess psychological aspect. Physical examination will be performed to determine the most tender cervical/ upper back muscles, and rule out operative condition. A simple swallowing test (3-oz water swallowing test) will be applied for dysphagia screening.

The patients will be maintained with routine, standardized physical therapy, oral medication, and stretch exercise after the injection. NDI, VAS, and SF-36 questionnaire will be re-collected at 1, 2, 3, 4, and 6 months after the injection session.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Subacute Cervical Pain
  • Subacute Upper Back Pain
Drug: Botulinum Toxin type a (Botox)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
July 2006
Not Provided

Inclusion Criteria:

  • Male or female 18 y/o or greater,
  • Subacute bilateral cervical/ upper back pain, pain of longer than 2 months and shorter than 6 months duration,
  • VAS pain score of 5 or greater for the cervical/ upper back pain for 4 week period before injection,
  • If female or child bearing potential, concurrent use of a reliable method of contraception.

Exclusion Criteria:

  • Known allergy or sensitivity to Botulinum toxin type A.
  • Any medical condition that may put the subject at increased risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
  • Use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function
  • Pregnancy, breast feeding, or planned pregnancy
  • Acute or operative pathology on cervical MRI
  • History of treatment for gatro-esophageal reflux disease
  • Abnormal finding on 3-oz water swallowing test on the initial screening visit
Both
18 Years to 70 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00282958
DAT0014
Not Provided
Not Provided
Palo Alto Institute for Research and Education, Inc
Allergan
Principal Investigator: Elaine Date, MD VA Palo Alto Health Care System
Principal Investigator: Henry Lew, MD, Ph.D VA Palo Alto Health Care System
Palo Alto Institute for Research and Education, Inc
January 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP